CVS Health (NYSE:CVS) Sets New 1-Year High on Strong Earnings

Key Points

• New 52-week high after earnings beat: Shares jumped to $88.63 after CVS reported Q1 adjusted EPS of $2.57 (vs. $2.21 consensus) and revenue of $100.43 billion (vs. $94.97B est.).
• Raised FY‑2026 guidance and margin tailwinds: Management lifted adjusted EPS guidance to $7.30–$7.50 and cited an improving Aetna medical‑benefit ratio plus PBM moves (greater biosimilar adoption) that should help reduce drug costs.
• Analyst sentiment positive: Multiple firms nudged up price targets and ratings, leaving CVS with a consensus "Moderate Buy" and an average price target near $94.61.

Shares of CVS Health Corporation (NYSE:CVS - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The stock traded as high as $88.63 and last traded at $87.8530, with a volume of 2539539 shares traded. The stock had previously closed at $80.69.

The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts' consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.97 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The company's revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.1%. CVS Health's dividend payout ratio is currently 192.75%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q1 earnings and revenue beat — CVS reported adjusted EPS of $2.57 (vs. $2.21 consensus) and revenue of $100.43B, topping estimates and marking a fifth consecutive quarterly beat for the company. Read More.
• Positive Sentiment: Raised FY‑2026 guidance — management raised adjusted EPS guidance to $7.30–$7.50 (above consensus ~7.16) and lifted cash‑flow guidance, reducing near‑term execution risk and improving street earnings visibility. Read More.
• Positive Sentiment: Insurance unit turnaround — Aetna’s medical benefit ratio improved to ~84.6% from 87.3% a year earlier, signaling better medical-cost control and driving a large portion of the beat. This directly supports margin recovery for the most volatile segment. Read More.
• Positive Sentiment: Pharmacy benefit moves to cut drug spend — CVS Caremark will expand adoption of lower‑cost interchangeable biosimilars (and will prefer those over some reference brands starting July 1), supporting lower drug costs and client savings for PBM flows. Read More.
• Positive Sentiment: Analyst and price‑target moves — HSBC nudged its price target higher (from $83 to $85), reflecting growing confidence in the company’s trajectory; analyst upgrades/target lifts add to buying pressure. Read More.
• Neutral Sentiment: Strategic/innovation updates — CVS Health Ventures made a small strategic investment in Fathom (autonomous coding) and other items (affiliations, clinic expansions) were reported; these are longer‑term operational items with limited near‑term EPS impact. Read More.
• Neutral Sentiment: Media/preview coverage — several previews and industry pieces highlighted Medicare Advantage exposure and cost trends; useful context but not new catalysts versus the confirmed results above. Read More.

Analysts Set New Price Targets

Several research firms recently commented on CVS. Robert W. Baird raised their target price on CVS Health from $92.00 to $94.00 and gave the stock an "outperform" rating in a report on Wednesday, April 15th. HSBC raised their target price on CVS Health from $83.00 to $85.00 and gave the stock a "hold" rating in a report on Tuesday. Bank of America dropped their target price on CVS Health from $100.00 to $95.00 and set a "buy" rating on the stock in a report on Tuesday, January 27th. The Goldman Sachs Group raised their target price on CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a report on Thursday, February 12th. Finally, Argus dropped their target price on CVS Health from $91.00 to $90.00 and set a "buy" rating on the stock in a report on Wednesday, January 28th. Twenty analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and a consensus price target of $94.61.

Institutional Investors Weigh In On CVS Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd raised its position in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after purchasing an additional 281 shares during the period. Swiss RE Ltd. purchased a new stake in shares of CVS Health in the 4th quarter valued at $26,000. Sankala Group LLC purchased a new stake in shares of CVS Health in the 4th quarter valued at $28,000. Global Trust Asset Management LLC raised its holdings in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. purchased a new stake in shares of CVS Health in the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The stock has a market cap of $110.86 billion, a PE ratio of 62.76, a P/E/G ratio of 0.86 and a beta of 0.60. The company has a fifty day moving average of $76.40 and a 200-day moving average of $77.96.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.